GEN Exclusives

More »

GEN News Highlights

More »
Sep 30, 2010

Positive Phase III Data Mean Cosmo and Santarus Plan 2011 NDA for Ulcerative Colitis Drug

  • Cosmo Pharmaceuticals and partner Santarus report positive data from a U.S.- and India-based Phase III trial with ulcerative colitis candidate, budesonide MMX®. The firms say they hope to submit an NDA for the drug to FDA during the second half of 2011, assuming positive results from a parallel European study due to report in November and following the completion of an ongoing placebo-controlled extended use trial.

    The latest Phase III data showed that treatment with budesonide MMX 9 mg for eight weeks was more effective than placebo at achieving clinical remission from mild-to-moderate active ulcerative colitis, as measured by the ulcerative colitis disease activity index (UCDAI) score. Of patients receiving once-daily budesonide MMX 9 mg, 17.9% achieved remission compared with 13.2% treated once daily with a 6 mg dose, 12.1% of patients given thrice-daily Asacol® (mesalamine) as a reference, and 7.4% of placebo-treated patients.

    The Phase III program for budesonide MMX also includes a European study, which is due to report within the next few weeks. It compared once-daily budesonide MMX 9 mg or 6 mg with placebo. The reference arm in this trial used Entocort EC® (budesonide) thrice daily. Cosmo notes that neither of the two Phase III studies was powered to show statistical differences between budesonide MMX, Asacol, and Entocort.

    Meanwhile an additional, FDA-requested 12-month extended use study is ongoing to support U.S. regulatory submission. This placebo-controlled trial, in the U.S. and India, is evaluating the long-term safety and tolerability of budesonide MMX 6 mg and efficacy of the drug in maintaining remission from ulcerative colitis. Study completion is scheduled for mid-2011.

    Budesonide MMX has been developed using Cosmo’s multi-matrix MMX system to allow the controlled release and distribution of budesonide throughout the length of the colon. Santarus negotiated exclusive rights to develop and commercialize budesonide MMX® and the antibiotic rifamycin SV MMX® in the U.S. back in 2008. In June 2010, Santarus started enrolling patients into the first Phase III trial evaluating rifamycin SV MMX for the treatment of travelers' diarrhea.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Connectomics Advocacy

How might connectomics maintain lasting support?